Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in High-Risk Japanese Subjects
NCT03571607Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2018
- Primary completion
- Nov 2018
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease, sponsored by Pfizer. Primary endpoints: Percentage of Participants Reporting Pre-Specified Local Reactions, Percentage of Participants Reporting Systemic Events and Use of Antipyretic or Pain Medication and 1 more. Started Jul 2018; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT03571607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03571607.